SCHEMBL3189079

SCHEMBL3189079

CCC1=C(C)C(=O)NS(=O)(=O)O1

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3180645 0.74 CA9 (0.43) CA9
SCHEMBL4272891 0.72 CA9 (0.35) CA9
SCHEMBL20464776 0.69 CA9 (0.32) CA9
SCHEMBL3180652 0.63 CA9 (0.34) CA9
SCHEMBL8187039 0.63 CA9 (0.41) CA9
SCHEMBL3180714 0.61 CA9 (0.59) CA9
SCHEMBL4278162 0.60 CA9 (0.38) CA9
SCHEMBL12282218 0.59 CA9 (0.37) CA9
SCHEMBL12261828 0.59 CA9 (0.37) CA9
SCHEMBL12261836 0.59 CA9 (0.37) CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260114475-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME MARS, INCORPORATED (US) 2026-04-30 US disclosed
EP-4593631-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME Mars, Incorporated (US) 2025-08-06 EP disclosed
WO-2024073025-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME MARS, INCORPORATED (US) 2024-04-04 WO disclosed
EP-4344552-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY, AND METHODS FOR PREPARING THE SAME MARS, INCORPORATED (US) 2024-04-03 EP disclosed
US-10251392-B2 Antimicrobial devices and compositions AVENT, INC. (US) 2019-04-09 US disclosed
US-10251392-B2 Antimicrobial devices and compositions AVENT, INC. (US) 2019-04-09 US disclosed
EP-2859961-A2 Methods and compositions for metal nanoparticle treated surfaces Avent, Inc. (US) 2015-04-15 EP disclosed
EP-1991365-B1 METHODS FOR FORMING SILVER-NANOPARTICLE TREATED SURFACES KIMBERLY CLARK CO (US) 2014-12-24 EP disclosed
US-20130122321-A1 Methods and Compositions for Metal Nanoparticle Treated Surfaces KIMBERLY-CLARK WORLDWIDE, INC. (US) 2013-05-16 US disclosed
US-20130122321-A1 Methods and Compositions for Metal Nanoparticle Treated Surfaces KIMBERLY-CLARK WORLDWIDE, INC. (US) 2013-05-16 US disclosed
US-20090318685-A1 METHOD FOR PRODUCING 3,4-DIHYDRO-1,2,3-OXATHIAZIN-4-ONE-2,2-DIOXIDE COMPOUND OR SALT THEREOF DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2009-12-24 US disclosed
US-20090035342-A1 Antimicrobial Devices and Compositions AVANOS MEDICAL SALES, LLC 2009-02-05 US disclosed
US-20090035342-A1 Antimicrobial Devices and Compositions AVANOS MEDICAL SALES, LLC 2009-02-05 US disclosed
US-20090035342-A1 Antimicrobial Devices and Compositions AVANOS MEDICAL SALES, LLC 2009-02-05 US disclosed
US-7408059-B2 6-methyl-3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide; cyclizing a beta-ketoamide-N-sulfonic acid with an acid anhydride DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2008-08-05 US disclosed
US-20070207335-A1 Methods and compositions for metal nanoparticle treated surfaces AVANOS MEDICAL SALES, LLC 2007-09-06 US disclosed
US-20070207335-A1 Methods and compositions for metal nanoparticle treated surfaces AVANOS MEDICAL SALES, LLC 2007-09-06 US disclosed
US-20070207335-A1 Methods and compositions for metal nanoparticle treated surfaces AVANOS MEDICAL SALES, LLC 2007-09-06 US disclosed
US-20050182255-A1 Method for producing 3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide compound or salt thereof DAICEL CHEMICAL INDUSTRIES, LTD. 2005-08-18 US disclosed
EP-1564211-A1 Method for producing 3,4-Dihydro-1,2,3-Oxathiazin-4-one-2,2-Dioxide compound or salt thereof Daicel Chemical Industries, Ltd. (JP) 2005-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182255-A1 Method for producing 3,4-dihydro-1,2,3-oxathiazin-4-one-2,2-dioxide compound or salt thereof CA2, HAO2, SRD5A2 CA9 124/4885
US-10251392-B2 Antimicrobial devices and compositions AAAS, AOC1, COL14A1 CA9 1224/4885
US-20090035342-A1 Antimicrobial Devices and Compositions AAAS, AOC1, COL14A1 CA9 1224/4885
US-20090318685-A1 METHOD FOR PRODUCING 3,4-DIHYDRO-1,2,3-OXATHIAZIN-4-ONE-2,2-DIOXIDE COMPOUND OR SALT THEREOF CA2, HAO2, KYAT1 CA9 110/4885
US-20260114475-A1 ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME PIGS, TAS2R13, CEL CA9 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.